Dr. Tilly Discusses Study of POLA-R-CHP in DLBCL

Herve Tilly, MD, PhD
Published: Wednesday, Jul 12, 2017



Herve Tilly, MD, PhD, Centre Henri Becquerel, discusses a study of polatuzumab vedotin combined with rituximab (Rituxan), cyclophosphamide, doxorubicin and prednisone (PLOA-R-CHP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
SELECTED
LANGUAGE


Herve Tilly, MD, PhD, Centre Henri Becquerel, discusses a study of polatuzumab vedotin combined with rituximab (Rituxan), cyclophosphamide, doxorubicin and prednisone (PLOA-R-CHP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x